Company profile: IO Biotech
1.1 - Company Overview
Company description
- Provider of immune-modulating cancer therapies built on its T-win technology, activating T cells against tumor and immune-suppressive cells. Offers IO102-IO103 T-win vaccines targeting IDO and PD-L1, used with anti-PD-1 therapy for metastatic melanoma, and runs Phase 2/3 trials with pembrolizumab in melanoma, lung, head and neck, and bladder cancers.
Products and services
- IO102-IO103: First-in-class combination of two T-win vaccines that activates T cells specific for IDO and PD-L1, administered with anti-PD-1 therapy for metastatic melanoma
- T-win® Technology: Proprietary immune-modulating vaccine platform that targets tumor cells and immune-suppressive cells, enabling activation of T cells specific for immune-suppressive molecules in the tumor microenvironment
- Clinical Trials: Clinical-stage evaluations of IO102-IO103 with pembrolizumab efficacy across melanoma, lung, head and neck, and bladder cancers in ongoing Phase 3 and Phase 2 studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IO Biotech
Elicio Therapeutics
HQ: United States
Website
- Description: Provider of lymph node-targeted vaccines designed to directly target the lymph nodes to treat aggressive cancers and infectious diseases; a pharmaceutical research company developing immuno-tumor vaccines to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elicio Therapeutics company profile →
Modifi Bio
HQ: United States
Website
- Description: Provider of direct DNA modification cancer therapeutics, including orally delivered molecules that selectively kill cancer cells by modifying tumor DNA while preserving healthy cells. Products target cancers with DNA repair defects and MGMT deficiency, with applications in glioblastomas, gliomas, and potentially other MGMT-deficient tumor types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modifi Bio company profile →
Igenica (closed)
HQ: United States
Website
- Description: Provider of antibody-based therapeutics for the treatment of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Igenica (closed) company profile →
Molecular Templates
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for cancer and other serious diseases, leveraging a proprietary engineered toxin body (ETB) platform with unique mechanisms of action. Pipeline includes MT-6402 (PD-L1), MT-8421 (CTLA-4), and MT-0169 (CD38). Operates a multi-product cGMP manufacturing facility in Austin, TX to supply clinical trial materials for internal and partnered ETB programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Templates company profile →
Zap Surgical
HQ: United States
Website
- Description: Provider of the ZAP-X gyroscopic radiosurgery platform for treating brain tumors, lesions, and head and neck conditions, utilizing a modern linear accelerator that eliminates radioactive source replacements. Offers vault-free design to reduce infrastructure costs, dual independent gantries for >1000 non-coplanar beam angles, tungsten-shielded collimation, and SRS webinars and clinical publications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zap Surgical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IO Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IO Biotech
2.2 - Growth funds investing in similar companies to IO Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IO Biotech
4.2 - Public trading comparable groups for IO Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →